See more : Ober SA (ALOBR.PA) Income Statement Analysis – Financial Results
Complete financial analysis of CSPC Pharmaceutical Group Limited (CSPCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CSPC Pharmaceutical Group Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Telefónica, S.A. (TEF) Income Statement Analysis – Financial Results
- Ainsworth Game Technology Limited (AINSF) Income Statement Analysis – Financial Results
- CervoMed Inc. (CRVO) Income Statement Analysis – Financial Results
- FTAC Hera Acquisition Corp. (HERAW) Income Statement Analysis – Financial Results
- Olympia Financial Group Inc. (OLY.TO) Income Statement Analysis – Financial Results
CSPC Pharmaceutical Group Limited (CSPCY)
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.60B | 31.59B | 33.59B | 28.03B | 25.06B | 18.47B | 12.92B | 11.08B | 9.54B | 8.76B | 7.77B | 3.34B | 5.97B | 6.63B | 6.19B | 6.01B | 4.67B | 3.55B | 3.32B | 2.61B | 2.64B |
| Cost of Revenue | 10.20B | 8.86B | 8.11B | 7.03B | 7.02B | 6.25B | 5.11B | 5.43B | 5.17B | 5.41B | 5.33B | 1.89B | 4.77B | 4.69B | 4.19B | 4.01B | 3.23B | 2.93B | 2.60B | 1.94B | 1.66B |
| Gross Profit | 24.40B | 22.73B | 25.47B | 21.00B | 18.04B | 12.22B | 7.81B | 5.65B | 4.37B | 3.35B | 2.45B | 1.45B | 1.20B | 1.94B | 2.00B | 2.01B | 1.44B | 614.98M | 721.96M | 672.10M | 986.22M |
| Gross Profit Ratio | 70.51% | 71.94% | 75.84% | 74.91% | 71.98% | 66.16% | 60.44% | 51.00% | 45.82% | 38.22% | 31.49% | 43.54% | 20.08% | 29.24% | 32.24% | 33.40% | 30.81% | 17.33% | 21.73% | 25.74% | 37.32% |
| Research & Development | 5.34B | 4.07B | 4.14B | 3.25B | 2.27B | 1.39B | 815.26M | 403.14M | 324.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.19B | 1.03B | 1.01B | 945.71M | 0.00 | 684.96M | 0.00 | 495.78M | 447.90M | 441.16M | 484.70M | 189.51M | 487.78M | 533.63M | 406.35M | 453.01M | 441.49M | 308.93M | 305.23M | 245.05M | 213.45M |
| Selling & Marketing | 9.14B | 9.08B | 10.44B | 9.38B | 0.00 | 6.44B | 0.00 | 2.50B | 1.90B | 1.43B | 1.02B | 609.77M | 422.25M | 443.86M | 517.57M | 414.53M | 355.24M | 0.00 | 0.00 | 140.05M | 100.79M |
| SG&A | 11.43B | 11.72B | 13.81B | 11.64B | 10.73B | 7.12B | 4.23B | 2.99B | 2.35B | 1.87B | 1.50B | 799.28M | 910.03M | 977.49M | 923.91M | 867.54M | 796.73M | 308.93M | 305.23M | 385.10M | 314.24M |
| Other Expenses | 0.00 | 715.52M | 545.69M | 0.00 | 0.00 | 181.19M | 0.00 | 284.26M | 211.51M | 138.54M | 25.05M | 39.54M | -16.19M | 90.99M | -45.79M | -10.36M | -116.04M | -303.63M | -251.34M | -3.97M | 12.74M |
| Operating Expenses | 16.72B | 15.80B | 17.95B | 14.89B | 13.00B | 8.23B | 4.90B | 3.28B | 2.56B | 2.01B | 1.53B | 838.82M | 893.84M | 1.07B | 965.62M | 936.19M | 866.82M | 308.93M | 305.23M | 381.12M | 326.98M |
| Cost & Expenses | 26.92B | 24.66B | 26.06B | 21.92B | 20.02B | 14.48B | 10.01B | 8.70B | 7.73B | 7.42B | 6.85B | 2.72B | 5.67B | 5.76B | 5.16B | 4.94B | 4.10B | 3.24B | 2.91B | 2.32B | 1.98B |
| Interest Income | 0.00 | 247.65M | 220.84M | 115.54M | 73.41M | 0.00 | 25.15M | 13.01M | 8.46M | 0.00 | 0.00 | -0.23 | 8.29M | -0.06 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | -0.48 | -0.61 |
| Interest Expense | 25.90M | 25.42M | 9.24M | 13.75M | 36.77M | 76.90M | 22.25M | 37.35M | 47.17M | 54.36M | 72.54M | 48.38M | 59.34M | 54.36M | 0.00 | 96.30M | 112.81M | 0.00 | 0.00 | 29.79M | 27.04M |
| Depreciation & Amortization | 1.12B | 1.07B | 1.04B | 906.92M | 784.21M | 727.46M | 699.04M | 568.51M | 506.83M | 487.95M | 512.82M | 154.05M | 482.83M | 489.31M | 442.15M | 414.93M | 394.39M | 333.19M | 272.77M | 195.85M | 155.63M |
| EBITDA | 8.53B | 7.60B | 9.28B | 8.09B | 5.35B | 5.32B | 4.19B | 3.25B | 2.76B | 2.29B | 1.54B | 2.55B | 782.59M | 1.60B | 1.70B | 1.69B | 1.06B | 435.48M | 427.86M | 616.92M | 822.98M |
| EBITDA Ratio | 24.66% | 25.32% | 25.51% | 25.02% | 23.26% | 25.50% | 22.35% | 26.29% | 24.22% | 20.72% | 19.70% | 61.39% | 13.10% | 20.32% | 22.98% | 24.63% | 21.33% | 9.44% | 12.88% | 18.78% | 31.03% |
| Operating Income | 7.68B | 6.93B | 7.53B | 6.11B | 5.05B | 4.05B | 2.89B | 2.39B | 1.80B | 1.33B | 1.02B | 1.90B | 299.77M | 856.86M | 980.39M | 1.07B | 602.14M | 1.60M | 155.09M | 294.44M | 664.38M |
| Operating Income Ratio | 22.20% | 21.94% | 22.41% | 21.79% | 20.13% | 21.95% | 22.35% | 21.54% | 18.91% | 15.15% | 13.10% | 56.78% | 5.02% | 12.93% | 15.84% | 17.73% | 12.89% | 0.05% | 4.67% | 11.28% | 25.14% |
| Total Other Income/Expenses | -290.75M | 827.27M | 562.11M | 672.74M | 579.27M | -559.92M | -586.02M | -289.80M | -397.87M | -42.29M | -43.75M | 1.24B | -19.81M | -46.92M | -39.40M | -96.92M | -112.81M | -64.49M | -261.63M | -162.22M | -18.93M |
| Income Before Tax | 7.39B | 7.76B | 8.23B | 7.17B | 5.18B | 3.95B | 2.90B | 2.36B | 1.77B | 1.30B | 974.90M | 1.85B | 254.42M | 822.20M | 991.22M | 975.61M | 489.33M | 1.60M | 155.09M | 265.46M | 640.31M |
| Income Before Tax Ratio | 21.36% | 24.56% | 24.49% | 25.57% | 20.67% | 21.41% | 22.41% | 21.31% | 18.54% | 14.80% | 12.54% | 55.49% | 4.26% | 12.41% | 16.01% | 16.22% | 10.48% | 0.05% | 4.67% | 10.17% | 24.23% |
| Income Tax Expense | 1.32B | 1.38B | 1.40B | 1.31B | 1.01B | 766.71M | 572.60M | 467.50M | 362.10M | 269.60M | 201.86M | 106.27M | 51.73M | 161.89M | 125.71M | 141.75M | 42.69M | -13.80M | -7.60M | 4.02M | 101.27M |
| Net Income | 5.87B | 5.35B | 5.61B | 5.16B | 4.21B | 3.21B | 2.32B | 1.88B | 1.39B | 1.01B | 760.11M | 1.74B | 188.70M | 640.61M | 854.69M | 828.17M | 446.64M | 15.40M | 162.69M | 260.63M | 536.07M |
| Net Income Ratio | 16.98% | 16.93% | 16.69% | 18.41% | 16.80% | 17.38% | 17.92% | 16.98% | 14.62% | 11.58% | 9.78% | 52.15% | 3.16% | 9.67% | 13.81% | 13.77% | 9.56% | 0.43% | 4.90% | 9.98% | 20.29% |
| EPS | 0.54 | 0.52 | 0.57 | 0.49 | 0.35 | 0.27 | 0.20 | 0.16 | 0.12 | 0.09 | 0.07 | 0.62 | 0.13 | 0.22 | 0.29 | 0.28 | 0.15 | 0.01 | 0.06 | 0.09 | 0.09 |
| EPS Diluted | 0.54 | 0.52 | 0.57 | 0.49 | 0.35 | 0.27 | 0.20 | 0.16 | 0.12 | 0.09 | 0.07 | 0.22 | 0.03 | 0.22 | 0.29 | 0.28 | 0.15 | 0.01 | 0.06 | 0.09 | 0.09 |
| Weighted Avg Shares Out | 11.87B | 11.92B | 11.95B | 11.95B | 11.95B | 11.98B | 11.70B | 11.44B | 11.34B | 11.34B | 11.29B | 8.80B | 8.29B | 2.95B | 2.95B | 2.95B | 2.95B | 2.95B | 2.95B | 2.95B | 2.91B |
| Weighted Avg Shares Out (Dil) | 11.87B | 11.92B | 11.95B | 11.96B | 11.96B | 11.98B | 11.70B | 11.53B | 11.44B | 11.46B | 11.29B | 8.80B | 8.29B | 2.95B | 2.95B | 2.95B | 2.95B | 2.95B | 2.95B | 2.95B | 2.95B |
Source: https://incomestatements.info
Category: Stock Reports